NEW ORLEANS — All doses and strengths of Allergan’s bimatoprost sustained release implant demonstrated efficacy in patients with open-angle glaucoma, E. Randy Craven, MD, said at the American Academy of Ophthalmology meeting.
Craven gave 24-month results of the phase 1/2 clinical trial of Bimatoprost SR, which was undertaken to evaluate the safety and effectiveness of the single use treatment in patients with ocular hypertension or open angle glaucoma. Patients were included in the study if they had responded to prostaglandins in the past, and if, after washout, IOP was between (Read more...)
Uncategorized